Distinct Clinical Outcomes and Biological Features of Specific KRAS Mutants in Human Pancreatic Cancer

Clinical Outcomes and Biological Characteristics Study Report for Pancreatic Cancer Patients with KRAS Mutations Research Background and Objective Pancreatic Ductal Adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer death by 2030. Only about 20% of PDAC patients are eligible for resection surgery, thus the five-year sur...